Bank of New York Mellon
ROIV icon

Bank of New York Mellon’s Roivant Sciences ROIV Stock Holding History

Bank of New York Mellon’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.7M Buy
2,790,266
+54,442
+2% +$1.61M 0.02% 680
2026
Q1 		$75.8M Sell
2,735,824
-167,305
-6% -$4.3M 0.01% 769
2025
Q4 		$63M Sell
2,903,129
-1,727,819
-37% -$34.1M 0.01% 870
2025
Q3 		$70.1M Buy
4,630,948
+124,548
+3% +$1.54M 0.01% 812
2025
Q2 		$50.8M Buy
4,506,400
+506,219
+13% +$5.49M 0.01% 987
2025
Q1 		$40.4M Buy
4,000,181
+560,641
+16% +$6.06M 0.01% 1090
2024
Q4 		$40.7M Buy
3,439,540
+510,398
+17% +$6.03M 0.01% 1146
2024
Q3 		$33.8M Buy
2,929,142
+242,604
+9% +$2.76M 0.01% 1270
2024
Q2 		$28.4M Buy
2,686,538
+58,541
+2% +$642K 0.01% 1375
2024
Q1 		$27.7M Buy
2,627,997
+1,309,483
+99% +$14.1M 0.01% 1393
2023
Q4 		$14.8M Buy
1,318,514
+130,586
+11% +$1.27M ﹤0.01% 1760
2023
Q3 		$13.9M Buy
1,187,928
+480,946
+68% +$5.44M ﹤0.01% 1753
2023
Q2 		$7.13M Buy
706,982
+568,197
+409% +$5.08M ﹤0.01% 2124
2023
Q1 		$1.02M Buy
138,785
+5,577
+4% +$45.9K ﹤0.01% 3122
2022
Q4 		$1.06M Buy
133,208
+14,145
+12% +$78.7K ﹤0.01% 3163
2022
Q3 		$384K Buy
119,063
+4,493
+4% +$17.4K ﹤0.01% 3717
2022
Q2 		$466K Buy
114,570
+67,296
+142% +$267K ﹤0.01% 3648
2022
Q1 		$233K Buy
47,274
+4,335
+10% +$28.6K ﹤0.01% 4162
2021
Q4 		$433K Buy
+42,939
New +$357K ﹤0.01% 3889

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bank of New York Mellon's ROIV Position: Q2 2026 in Review

Bank of New York Mellon increased its Roivant Sciences (ROIV) stake by 2% in Q2 2026, buying an estimated $1.61M and bringing the position to 2,790,266 shares worth $98.7M. The position accounts for 0.02% of the portfolio, ranked #680.

Bank of New York Mellon first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Bank of New York Mellon held 2,790,266 shares of Roivant Sciences worth $98.7M as of Q2 2026.
  • Bank of New York Mellon bought 54,442 Roivant Sciences shares in Q2 2026, an estimated $1.61M.
  • Roivant Sciences made up 0.02% of Bank of New York Mellon's portfolio in Q2 2026, its #680 holding.
  • Bank of New York Mellon first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.